Sulindac Sulfide Reverses Aberrant Self-Renewal of Progenitor Cells Induced by AML-Associated Fusion Proteins
Author Information
Author(s): Steinert Gunnar, Oancea Claudia, Roos Jessica, Hagemeyer Heike, Maier Thorsten, Ruthardt Martin, Puccetti Elena
Primary Institution: Goethe-University, Frankfurt, Germany
Hypothesis
Does Sulindac Sulfide effectively reverse the leukemic phenotype induced by PML/RARα and PLZF/RARα fusion proteins?
Conclusion
Sulindac Sulfide inhibits leukemic cell growth and promotes differentiation in X-RARα-positive progenitor cells.
Supporting Evidence
- SSi downregulated β-catenin and γ-catenin in X-RARα-expressing cells.
- SSi reversed the leukemic phenotype by reducing stem cell capacity.
- SSi increased differentiation potential in X-RARα-positive HSCs.
- Clinical doses of SSi induced apoptosis in leukemic cells.
- SSi inhibited Wnt signaling and downregulated Wnt target genes.
Takeaway
Sulindac Sulfide can help treat leukemia by stopping cancer cells from growing and helping them to mature into normal cells.
Methodology
The study used cell lines and mouse models to assess the effects of Sulindac Sulfide on leukemic cells and progenitor cells.
Limitations
The study primarily focused on in vitro and in vivo models, which may not fully replicate human responses.
Participant Demographics
8 female C57BL/6N mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website